Increased levels of SELL correlate with favorable clinical prognosis in our AML cohort and increased event-free survival in publicly available AML patient data sets. (A) SELL mRNA expression levels (normalized to β-ACTIN) in AML patients with favorable (n = 9), intermediate (n = 38), or adverse (n = 8) prognosis. Data (favorable vs adverse) were compared using the Student t test. (B) SELL/CD62L expression levels analyzed by flow cytometry in AML blasts from patients with favorable (n = 7), intermediate (n = 38), or adverse (n = 7) prognosis. Data (favorable vs adverse) were compared using the Student t test, and significance is indicated by P = .058. (C) Gene signatures from publicly available AML patient data sets (n = 740) were compared, showing that patients with high expression of the STAT3β signature (SELL, ITGAX, CD177) had better survival compared with patients with low expression in 740 AML patients (HR, 0.78; P = .33). *P < .05.